In part 5, the conclusion of this Exclusive Interview, Richard Pratley talks with Diabetes in Control Publisher Steve Freed during the AACE meeting in Austin, Texas about his anticipated visit to the ADA convention.
Richard E. Pratley, MD serves as the Medical Director of the Florida Hospital Diabetes Institute. He is also a senior scientist at the Florida Hospital /Sanford-Burnham Translational Research Institute for Metabolism and Diabetes.
Transcript of this video segment:
Steve Freed: ADA is coming up next month. Is there anything that you’re looking forward to as far as announcements that you consider exciting?
Richard Pratley: There will a lot of exciting data from large clinical trials. I’m presenting at the DEVOTE symposium where we’re going to presenting the results of a cardiovascular outcome study with the insulin degludec that’s very interesting because it was the first study that compared a basal insulin with insulin glargine standard of care. There’s also going to be data on the CANVAS study, I believe, released, which is another SGLT-2 inhibitor looking at cardiovascular outcomes and I am also presenting follow up data from the LEADER study, the cardiovascular outcomes study with liraglutide. I think there are a lot of existing data that will be presenting at the ADA that will have impact on the practice of diabetes management.
Steve Freed: Thank you for joining us today and enjoy the rest of your stay here.